We recently published a list of 10 Stocks With At Least $20 Million In Insider Spending Recently. In this article, we are ...

Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...

Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s differentiated obesity drug pipeline and potential for significant upside. Metsera is also viewed as a ...

Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...

We recently published a list of 10 Stocks With At Least $10 Million In Insider Spending Recently. In this article, we are ...

Metsera has technologies and drug candidates intended to improve on these limitations. With key clinical trial readouts expected this year, the company took its story to investors through an IPO.

In other recent news, Metsera Inc has made significant strides with its initial public offering (IPO), which opened 42% higher than its offering price. The company initially set its IPO at $18.00 ...

In other recent news, Metsera Inc has made significant strides with its initial public offering (IPO), which opened 42% higher than its offering price. The company initially set its IPO at $18.00 per ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.